Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Proc Natl Acad Sci U S A ; 117(37): 22962-22966, 2020 09 15.
Article in English | MEDLINE | ID: mdl-32868418

ABSTRACT

Gonadal hormones are linked to mechanisms that govern appetitive behavior and its suppression. Estrogens are synthesized from androgens by the enzyme aromatase, highly expressed in the ovaries of reproductive-aged women and in the brains of men and women of all ages. We measured aromatase availability in the amygdala using positron emission tomography (PET) with the aromatase inhibitor [11C]vorozole in a sample of 43 adult, normal-weight, overweight, or obese men and women. A subsample of 27 also completed personality measures to examine the relationship between aromatase and personality traits related to self-regulation and inhibitory control. Results indicated that aromatase availability in the amygdala was negatively associated with body mass index (BMI) (in kilograms per square meter) and positively correlated with scores of the personality trait constraint independent of sex or age. Individual variations in the brain's capacity to synthesize estrogen may influence the risk of obesity and self-control in men and women.


Subject(s)
Appetite/physiology , Estrogens/metabolism , Obesity/metabolism , Adult , Aged , Amygdala/diagnostic imaging , Amygdala/metabolism , Androgens , Aromatase/analysis , Aromatase Inhibitors , Body Mass Index , Brain/metabolism , Estrogens/physiology , Female , Humans , Lipogenesis , Male , Middle Aged , Positron-Emission Tomography/methods , Self-Control
2.
Appl Radiat Isot ; 102: 48-54, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25980658

ABSTRACT

In this research, we aim to directly measure the specific activity (SA) of the carbon-11 cyanide ([(11)C]CN¯) produced by our in-house built automated [(11)C]HCN production system and to identify the major sources of (12)C-cyanide ((12)CN¯). The [(11)C]CN¯ is produced from [(11)C]CO2, which is generated by the (14)N(p,α)(11)C nuclear reaction using a cyclotron. Direct measurement of cyanide concentrations was accomplished using a relatively inexpensive, and easy to use ion selective electrode (ISE) which offered an appropriate range of sensitivity for detecting mass. Multiple components of the [(11)C]HCN production system were isolated in order to determine their relative contributions to (12)CN¯ mass. It was determined that the system gases were responsible for approximately 30% of the mass, and that the molecular sieve/nickel furnace unit contributed approximately 70% of the mass. Beam on target (33µA for 1 and 10min) did not contribute significantly to the mass. Additionally, we compared the SA of our [(11)C]HCN precursor determined using the ISE to the SA of our current [(11)C]CN¯ derived radiotracers determined by HPLC to assure there was no significant difference between the two methods. These results are the first reported use of an ion selective electrode to determine the SA of no-carrier-added cyanide ion, and clearly show that it is a valuable, inexpensive and readily available tool suitable for this purpose.


Subject(s)
Carbon Radioisotopes/analysis , Cyanides/analysis , Ion-Selective Electrodes , Cyanides/chemistry , Positron-Emission Tomography/methods
3.
J Nucl Med ; 56(4): 580-5, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25698781

ABSTRACT

UNLABELLED: Aromatase, the last and obligatory enzyme catalyzing estrogen biosynthesis from androgenic precursors, can be labeled in vivo with (11)C-vorozole. Aromatase inhibitors are widely used in breast cancer and other endocrine conditions. The present study aimed to provide baseline information defining aromatase distribution in healthy men and women, against which its perturbation in pathologic situations can be studied. METHODS: (11)C-vorozole (111-296 MBq/subject) was injected intravenously in 13 men and 20 women (age range, 23-67 y). PET data were acquired over a 90-min period. Each subject had 4 scans, 2 per day separated by 2-6 wk, including brain and torso or pelvis scans. Young women were scanned at 2 discrete phases of the menstrual cycle (midcycle and late luteal). Men and postmenopausal women were also scanned after pretreatment with a clinical dose of the aromatase inhibitor letrozole. Time-activity curves were obtained, and standardized uptake values (SUV) were calculated for major organs including brain, heart, lungs, liver, kidneys, spleen, muscle, bone, and male and female reproductive organs (penis, testes, uterus, ovaries). Organ and whole-body radiation exposures were calculated using OLINDA software. RESULTS: Liver uptake was higher than uptake in any other organ but was not blocked by pretreatment with letrozole. Mean SUVs were higher in men than in women, and brain uptake was blocked by letrozole. Male brain SUVs were also higher than SUVs in any other organ (ranging from 0.48 ± 0.05 in lungs to 1.5 ± 0.13 in kidneys). Mean ovarian SUVs (3.08 ± 0.7) were comparable to brain levels and higher than in any other organ. Furthermore, ovarian SUVs in young women around the time of ovulation (midcycle) were significantly higher than those measured in the late luteal phase, whereas aging and cigarette smoking reduced (11)C-vorozole uptake. CONCLUSION: PET with (11)C-vorozole is useful for assessing physiologic changes in estrogen synthesis capacity in the human body. Baseline levels in breasts, lungs, and bones are low, supporting further investigation of this tracer as a new tool for detection of aromatase-overexpressing primary tumors or metastases in these organs and optimization of treatment in cancer and other disorders in which aromatase inhibitors are useful.


Subject(s)
Aromatase Inhibitors/chemistry , Aromatase/chemistry , Nitriles/chemistry , Positron-Emission Tomography/methods , Triazoles/chemistry , Adult , Age Factors , Aged , Diagnostic Imaging , Female , Healthy Volunteers , Humans , Letrozole , Liver/drug effects , Liver/radiation effects , Male , Middle Aged , Radiometry , Radiopharmaceuticals , Reproducibility of Results , Sex Factors , Software , Whole-Body Irradiation , Young Adult
4.
Neuropsychopharmacology ; 40(3): 650-7, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25249059

ABSTRACT

Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson's disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared with equal doses of conventional selegiline. Although there is indirect evidence that Zydis selegiline at high doses loses its selectivity for MAO-B, there is no direct evidence that it also inhibits brain MAO-A in humans. We measured brain MAO-A in 18 healthy men after a 28-day treatment with Zydis selegiline (2.5, 5.0, or 10 mg/day) and in 3 subjects receiving the selegiline transdermal system (Emsam patch, 6 mg/day) using positron emission tomography and the MAO-A radiotracer [(11)C]clorgyline. We also measured dopamine transporter (DAT) availability in three subjects from the 10 mg group. The 10 mg Zydis selegiline dose significantly inhibited MAO-A (36.9±19.7%, range 11-70%, p<0.007)) but not DAT; and while Emsam also inhibited MAO-A (33.2±28.9 (range 9-68%) the difference did not reach significance (p=0.10)) presumably because of the small sample size. Our results provide the first direct evidence of brain MAO-A inhibition in humans by formulations of selegiline, which are currently postulated but not verified to target brain MAO-A in addition to MAO-B.


Subject(s)
Brain/drug effects , Brain/enzymology , Monoamine Oxidase Inhibitors/pharmacology , Monoamine Oxidase/metabolism , Selegiline/pharmacology , Administration, Cutaneous , Administration, Oral , Adolescent , Adult , Brain/metabolism , Carbon Radioisotopes/metabolism , Clorgyline/metabolism , Cocaine/metabolism , Dopamine Plasma Membrane Transport Proteins/drug effects , Dopamine Plasma Membrane Transport Proteins/metabolism , Dose-Response Relationship, Drug , Functional Neuroimaging , Humans , Male , Monoamine Oxidase Inhibitors/administration & dosage , Positron-Emission Tomography , Selegiline/administration & dosage , Young Adult
5.
Appl Radiat Isot ; 94: 338-343, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25305526

ABSTRACT

We constructed a hand-held device to efficiently trap [(11)C]CO2 from the cyclotron target, safely transport up to 3.7GBq (100mCi) doses to remote sites and release it without the need for a liquid cryogen. The system consists of a 180W furnace and a miniature molecular sieve trap (80-100mg; 80-100mesh 13×) placed inside a lead pig weighing 11.1kg. The overall [(11)C]CO2 delivery efficiency of the device is ~82% (> 99% trapping efficiency). Radiation dose rates measured at 30cm from the surface of the pig are <43.5µSv/h (5mR/h) up to 2.59GBq (70mCi).


Subject(s)
Carbon Dioxide/administration & dosage , Carbon Dioxide/chemistry , Heating/instrumentation , Radiation Protection/instrumentation , Rheology/instrumentation , Specimen Handling/instrumentation , Carbon Dioxide/isolation & purification , Carbon Radioisotopes/chemistry , Carbon Radioisotopes/isolation & purification , Equipment Design , Equipment Failure Analysis , Miniaturization , Radiopharmaceuticals/chemistry , Radiopharmaceuticals/isolation & purification
6.
Appl Radiat Isot ; 91: 155-60, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24946093

ABSTRACT

An improved production procedure and formulation method for the carbon-11 radiolabeled phytohormone, 3-indolyl-[l-(11)C]acetic acid ([(11)C]IAA), was developed by modifying selected original reaction parameters. This updated procedure both doubled the yield (from 25.9±6.7% (n=12) to 61.0±0.3% (n=10)) and increased the concentration (0.2-0.4 GBq/0.15-0.3 mL), enabling us to provide the radiotracer [(11)C]IAA suitable for in vivo phyto-PET-imaging studies. The specific activity was improved by more than a factor of three (26.7±5.6 GBq/µmol to 82.5±36.1 GBq/µmol). The total synthesis time for both production and formulation was 81.8±3.0 min (n=10). In addition, a streamlined semi-remote controlled production system, containing five processing modules, was designed and built for routine [(11)C]IAA production. This integrated system facilitated routine high radiation level production of [(11)C]IAA while minimizing radiation exposure to the production chemists.


Subject(s)
Carbon Radioisotopes/chemistry , Indoleacetic Acids/chemical synthesis , Radiopharmaceuticals/chemical synthesis , Automation/methods , Indoleacetic Acids/chemistry , Isotope Labeling/instrumentation , Isotope Labeling/methods , Plant Growth Regulators/chemical synthesis , Positron-Emission Tomography/methods
7.
Nucl Med Biol ; 38(2): 191-200, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21315274

ABSTRACT

INTRODUCTION: PET imaging in plants is receiving increased interest as a new strategy to measure plant responses to environmental stimuli and as a tool for phenotyping genetically engineered plants. PET imaging in plants, however, poses new challenges. In particular, the leaves of most plants are so thin that a large fraction of positrons emitted from PET isotopes ((18)F, (11)C, (13)N) escape while even state-of-the-art PET cameras have significant partial-volume errors for such thin objects. Although these limitations are acknowledged by researchers, little data have been published on them. METHODS: Here we measured the magnitude and distribution of escaping positrons from the leaf of Nicotiana tabacum for the radionuclides (18)F, (11)C and (13)N using a commercial small-animal PET scanner. Imaging results were compared to radionuclide concentrations measured from dissection and counting and to a Monte Carlo simulation using GATE (Geant4 Application for Tomographic Emission). RESULTS: Simulated and experimentally determined escape fractions were consistent. The fractions of positrons (mean±S.D.) escaping the leaf parenchyma were measured to be 59±1.1%, 64±4.4% and 67±1.9% for (18)F, (11)C and (13)N, respectively. Escape fractions were lower in thicker leaf areas like the midrib. Partial-volume averaging underestimated activity concentrations in the leaf blade by a factor of 10 to 15. CONCLUSIONS: The foregoing effects combine to yield PET images whose contrast does not reflect the actual activity concentrations. These errors can be largely corrected by integrating activity along the PET axis perpendicular to the leaf surface, including detection of escaped positrons, and calculating concentration using a measured leaf thickness.


Subject(s)
Artifacts , Electrons , Nicotiana , Plant Leaves , Positron-Emission Tomography/methods , Biological Transport , Plant Leaves/metabolism , Radioactive Tracers , Nicotiana/metabolism
8.
Synapse ; 64(11): 801-7, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20842717

ABSTRACT

Aromatase catalyzes the last step in estrogen biosynthesis. Brain aromatase is involved in diverse neurophysiological and behavioral functions including sexual behavior, aggression, cognition, and neuroprotection. Using positron emission tomography (PET) with the radiolabeled aromatase inhibitor [N-methyl-(11)C]vorozole, we characterized the tracer distribution and kinetics in the living human brain. Six young, healthy subjects, three men and three women, were administered the radiotracer alone on two separate occasions. Women were scanned in distinct phases of the menstrual cycle. Specificity was confirmed by pretreatment with a pharmacological (2.5 mg) dose of the aromatase inhibitor letrozole. PET data were acquired over a 90-min period and regions of interest placed over selected brain regions. Brain and plasma time activity curves, corrected for metabolites, were used to derive kinetic parameters. Distribution volume (V(T)) values in both men and women followed the following rank order: thalamus > amygdala = preoptic area > medulla (inferior olive) > accumbens, pons, occipital and temporal cortex, putamen, cerebellum, and white matter. Pretreatment with letrozole reduced V(T) in all regions, though the size of the reduction was region-dependent, ranging from ∼70% blocking in thalamus andpreoptic area to ∼10% in cerebellum. The high levels of aromatase in thalamus and medulla (inferior olive) appear to be unique to humans. These studies set the stage for the noninvasive assessment of aromatase involvement in various physiological and pathological processes affecting the human brain.


Subject(s)
Aromatase Inhibitors/pharmacokinetics , Aromatase/metabolism , Brain/diagnostic imaging , Brain/enzymology , Positron-Emission Tomography , Triazoles/pharmacokinetics , Adult , Brain/drug effects , Brain Mapping , Female , Humans , Male , Protein Binding/drug effects , Radiopharmaceuticals/pharmacokinetics , Tissue Distribution , Young Adult
9.
Nucl Med Biol ; 36(3): 323-34, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19324278

ABSTRACT

INTRODUCTION: We reinvestigated the synthesis of [N-methyl-(11)C]vorozole, a radiotracer for aromatase, and discovered the presence of an N-methyl isomer which was not removed in the original purification method. Herein we report the preparation and positron emission tomography (PET) studies of pure [N-methyl-(11)C]vorozole. METHODS: Norvorozole was alkylated with [(11)C]methyl iodide as previously described and also with unlabeled methyl iodide. A high-performance liquid chromatography (HPLC) method was developed to separate the regioisomers. Nuclear magnetic resonance (NMR) spectroscopy ((13)C and 2D-nuclear Overhauser effect spectroscopy NMR) was used to identify and assign structures to the N-methylated products. Pure [N-methyl-(11)C]vorozole and the contaminating isomer were compared by PET imaging in the baboon. RESULTS: Methylation of norvorozole resulted in a mixture of isomers (1:1:1 ratio) based on new HPLC analysis using a pentafluorophenylpropyl bonded silica column, in which vorozole coeluted one of its isomers under the original HPLC conditions. Baseline separation of the three labeled isomers was achieved. The N-3 isomer was the contaminant of vorozole, thus correcting the original assignment of isomers. PET studies of pure [N-methyl-(11)C]vorozole with and without the contaminating N-3 isomer revealed that only [N-methyl-(11)C]vorozole binds to aromatase. [N-methyl-(11)C]Vorozole accumulated in all brain regions with highest accumulation in the aromatase-rich amygdala and preoptic area. Accumulation was blocked with vorozole and letrozole consistent with reports of some level of aromatase in many brain regions. CONCLUSIONS: The discovery of a contaminating labeled isomer and the development of a method for isolating pure [N-methyl-(11)C]vorozole combine to provide a new scientific tool for PET studies of the biology of aromatase and for drug research and development.


Subject(s)
Aromatase/metabolism , Triazoles/chemical synthesis , Triazoles/metabolism , Alkylation , Animals , Aromatase/analysis , Brain/diagnostic imaging , Brain/metabolism , Chromatography, High Pressure Liquid , Female , Hydrocarbons, Iodinated/chemistry , Magnetic Resonance Spectroscopy , Papio , Positron-Emission Tomography , Radioactive Tracers , Stereoisomerism , Time Factors , Triazoles/chemistry
10.
Neuroimage ; 41(3): 1051-66, 2008 Jul 01.
Article in English | MEDLINE | ID: mdl-18442926

ABSTRACT

We investigated an imaging strategy that provides simultaneous measurements of radiotracer binding and behavior in awake, freely moving animals. In this strategy, animals are injected intravenously (i.v.) through a catheterized line and permitted to move freely for 30 min during uptake of the imaging agent, in this case 11C-raclopride. After this Awake Uptake period, animals are anesthetized and scanned for 25 min. We tested the utility of this strategy for measuring changes in striatal 11C-raclopride binding under control conditions (awake and freely moving in the home cage) and with several drug challenges: a loading dose of unlabeled raclopride, pretreatment with methamphetamine (METH) or pretreatment with gamma-vinyl-GABA [S+-GVG] followed by METH. An additional group of animals underwent a stress paradigm that we have previously shown increases brain dopamine. For drug challenge experiments, the change in 11C-raclopride binding was compared to data from animals that were anesthetized for the uptake period ("Anesthetized Uptake") and full time activity curves were used to calculate 11C-raclopride binding. Regardless of the drug treatment protocol, there was no difference in 11C-raclopride striatum to cerebellum ratio between the Awake versus the Anesthetized Uptake conditions. Awake and Anesthetized groups demonstrated over 90% occupancy of dopamine receptors with a loading dose of cold raclopride, both groups demonstrated approximately 30% reduction in 11C-raclopride binding from METH pretreatment and this effect was modulated to the same degree by GVG under both uptake conditions. Restraint during Awake Uptake decreased 11C-raclopride binding by 29%. These studies support a unique molecular imaging strategy in which radiotracer uptake occurs in freely moving animals, after which they are anesthetized and scanned. This imaging strategy extends the applicability of small animal PET to include functional neurotransmitter imaging and the neurochemical correlates of behavioral tasks.


Subject(s)
Brain/metabolism , Dopamine Antagonists/metabolism , Dopamine/metabolism , Positron-Emission Tomography/methods , Raclopride/metabolism , Animals , Brain/drug effects , Carbon Radioisotopes/metabolism , Dopamine Agents/pharmacology , GABA Agents/pharmacology , Image Processing, Computer-Assisted , Male , Methamphetamine/pharmacology , Movement/physiology , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Tissue Distribution , Vigabatrin/pharmacology
11.
Pharmacol Biochem Behav ; 89(1): 101-5, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18096214

ABSTRACT

INTRODUCTION: Acetone is an ubiquitous ingredient in many household products (e.g., glue solvents, air fresheners, adhesives, nail polish, and paint) that is putatively abused; however, there is little empirical evidence to suggest that acetone alone has any abuse liability. Therefore, we systematically investigated the conditioned response to inhaled acetone in a place conditioning apparatus. METHOD: Three groups of male, Sprague-Dawley rats were exposed to acetone concentrations of 5000, 10,000 or 20,000 ppm for 1 h in a conditioned place preference apparatus alternating with air for 6 pairing sessions. A place preference test ensued in an acetone-free environment. To test the preference of acetone as a function of pairings sessions, the 10,000 ppm group received an additional 6 pairings and an additional group received 3 pairings. The control group received air in both compartments. Locomotor activity was recorded by infrared photocells during each pairing session. RESULTS: We noted a dose response relationship to acetone at levels 5000-20,000 ppm. However, there was no correlation of place preference as a function of pairing sessions at the 10,000 ppm level. Locomotor activity was markedly decreased in animals on acetone-paired days as compared to air-paired days. CONCLUSION: The acetone concentrations we tested for these experiments produced a markedly decreased locomotor activity profile that resemble CNS depressants. Furthermore, a dose response relationship was observed at these pharmacologically active concentrations, however, animals did not exhibit a positive place preference.


Subject(s)
Acetone/pharmacology , Conditioning, Operant/drug effects , Solvents/pharmacology , Acetone/administration & dosage , Administration, Inhalation , Animals , Area Under Curve , Dose-Response Relationship, Drug , Male , Motor Activity/drug effects , Rats , Rats, Sprague-Dawley , Solvents/administration & dosage
13.
Psychopharmacology (Berl) ; 186(2): 159-67, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16703400

ABSTRACT

RATIONALE: Children and adolescents will readily abuse household products that contain solvents such as toluene. It is likely that reinforcing exposures to toluene alter brain glucose metabolism. OBJECTIVE: Using an animal model of drug reinforcement, we sought to identify a metabolic signature of toluene abuse in the adolescent rodent brain. Small animal PET (microPET), in combination with the glucose analog radiotracer, (18)FDG, were used to evaluate the metabolic consequences of inhaled toluene. METHODS: The exposure protocol paralleled our previously established method for assessing the conditioned reinforcing effects of toluene (5,000 ppm) using the conditioned place preference (CPP) paradigm. Animals were scanned at baseline and 2 h after the last exposure. Follow-up (18)FDG scans occurred 1 day, 3 weeks, and 2 months later. RESULTS: After six pairings, 38% of the animals preferred the toluene paired chamber and 25% were averse. The immediate metabolic effect in toluene-exposed animals was a 20% decline in whole brain (18)FDG uptake. Twenty-four hours following the last exposure, the whole brain decline was 40%, and 2 months later, the decline was 30% of pretoluene levels. A region-by-region analysis demonstrated significant additional decreases in the pons, cerebellum, striatum, midbrain, temporal cortex, and hippocampus. Two months after toluene cessation, regions of complete metabolic recovery were the thalamus and cerebellum; however, the temporal cortex did not recover. CONCLUSIONS: Brain uptake of (18)FDG appears to be a useful tool for examining the metabolic impact of toluene abuse, which include a profound decline followed by region-specific recovery after cessation.


Subject(s)
Brain/metabolism , Inhalation Exposure/adverse effects , Solvents/toxicity , Substance-Related Disorders/metabolism , Toluene/toxicity , Animals , Brain/diagnostic imaging , Brain/drug effects , Brain Mapping , Disease Models, Animal , Fluorodeoxyglucose F18 , Male , Rats , Rats, Sprague-Dawley , Reinforcement, Psychology , Substance-Related Disorders/diagnostic imaging , Substance-Related Disorders/etiology , Substance-Related Disorders/psychology , Tomography, Emission-Computed
14.
J Neurosci Methods ; 155(2): 272-84, 2006 Sep 15.
Article in English | MEDLINE | ID: mdl-16519945

ABSTRACT

Despite the widespread use of chronic brain implants in experimental and clinical settings, the effects of these long-term procedures on brain metabolism and receptor expression remain largely unknown. Under the hypothesis that intracerebral microdialysis transiently alters tissue metabolism, we performed a series of 18FDG microPET scans prior to and following surgical implantation of microdialysis cannulae. Parallel microPET measures using the competitive dopamine (DA) D2 receptor antagonist, 11C-raclopride, provided an assay of DA stability in these same animals. 18FDG scans were performed prior to microdialysis cannulation and again at 2, 12, 24, 48, 120, 168, 360 and 500 h (0.2, 0.5, 1, 2, 5, 7, 15 and 25 days). Separate animals received a sham surgery and the control group had no surgical intervention. For the first 24 h (scans at 2, 12 and 24 h post-surgery) uptake was reduced in both hemispheres. However, by 48 h, contralateral uptake had returned to pre-surgical levels. The striking finding was that from 48 to 500 h, the microdialysis cannulation produced widespread ipsilateral reductions in 18FDG uptake that encompassed the entire hemisphere. Despite the extent and persistence of these reductions, 11C-raclopride binding and ECF DA concentrations remained stable.


Subject(s)
Brain/diagnostic imaging , Microdialysis/methods , Positron-Emission Tomography , Animals , Brain/anatomy & histology , Brain/drug effects , Brain Mapping , Dopamine Antagonists/pharmacokinetics , Fluorodeoxyglucose F18/metabolism , Male , Raclopride/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Rats , Time Factors
15.
Nucl Med Biol ; 33(1): 71-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16459261

ABSTRACT

INTRODUCTION: One strength of small animal imaging is the ability to obtain longitudinal measurements within the same animal, effectively reducing the number of animals needed and increasing statistical power. However, the variability of within-rodent brain glucose uptake after an intraperitoneal injection across an extended time has not been measured. METHODS: Small animal imaging with 2-deoxy-2-[(18)F]-fluoro-D-glucose ((18)FDG) was used to determine the variability of a 50-min brain (18)FDG uptake following an intraperitoneal injection over time in awake male and female Sprague-Dawley rodents. RESULTS: After determining the variability of an intraperitoneal injection in the awake rat, we found that normalization of brain (18)FDG uptake for (1) injected dose and body weight or (2) body weight, plasma glucose concentration and injected dose resulted in a coefficient of variation (CV) of 15%. However, if we normalized regional uptake to whole brain to compare relative regional changes, the CV was less than 5%. Normalized cerebral (18)FDG uptake values were reproducible for a 2-week period in young adult animals. After 1 year, both male and female animals had reduced whole-brain uptake, as well as reduced regional hippocampal and striatal (18)FDG uptake. CONCLUSION: Overall, our results were similar to findings in previous rodent and human clinical populations; thus, using a high throughput study with intraperitoneal (18)FDG is a promising preclinical model for clinical populations. This is particularly relevant for measuring changes in brain function after experimental manipulation, such as long-term pharmacological administration.


Subject(s)
Brain/diagnostic imaging , Brain/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Animals , Female , Fluorodeoxyglucose F18/administration & dosage , Injections, Intraperitoneal , Kinetics , Male , Metabolic Clearance Rate , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Sensitivity and Specificity , Sex Factors
16.
Synapse ; 57(2): 85-90, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15906391

ABSTRACT

Anorexia nervosa is a life-threatening psychiatric disorder characterized by severe weight loss and high rates of comorbidity and mortality. The current study assessed the feasibility of using microPET imaging to study the effects of chronic food restriction in an animal model of anorexia nervosa. To establish preliminary support for this model, we hypothesized that chronic food restriction would decrease relative 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) uptake in the rat, in effect modeling cerebral glucose hypometabolism reported in the clinical population of anorexia nervosa. Nine adolescent Wistar female rats received a baseline 18FDG scan. The control group received free access to food for a period of 25 days. The food restricted (FR) group received 40% of their baseline daily food intake until a 30% weight loss occurred; body weight was then maintained at 70% of baseline by adjusting daily food intake. The FR group also had free access to a running wheel for a mean period of 10.8+/-6.1 days. Both groups received a follow-up 18FDG scan. Relative 18FDG uptake was significantly increased in the cerebellum and significantly decreased in the hippocampus and striatum in the FR group compared to controls. Moreover, there was a trend towards a decrease in relative 18FDG uptake in the thalamus in the FR compared to control group. This is the first study to establish support for the use of microPET imaging in an animal model of anorexia nervosa as a means for studying the neurobiological changes that occur due to chronic food restriction.


Subject(s)
Anorexia Nervosa/diagnostic imaging , Brain/diagnostic imaging , Energy Metabolism/physiology , Food Deprivation/physiology , Positron-Emission Tomography/methods , Animals , Anorexia Nervosa/metabolism , Anorexia Nervosa/physiopathology , Body Weight/physiology , Brain/metabolism , Brain/physiopathology , Cerebellum/diagnostic imaging , Cerebellum/metabolism , Cerebellum/physiopathology , Disease Models, Animal , Down-Regulation/physiology , Feasibility Studies , Female , Fluorodeoxyglucose F18/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Glucose/metabolism , Predictive Value of Tests , Prosencephalon/diagnostic imaging , Prosencephalon/metabolism , Prosencephalon/physiopathology , Rats , Rats, Wistar , Up-Regulation/physiology
17.
J Neurosci Methods ; 144(1): 25-34, 2005 May 15.
Article in English | MEDLINE | ID: mdl-15848236

ABSTRACT

In the field of small animal positron emission tomography (PET), the assumptions underlying human and primate kinetic models may not be sustained in rodents. That is, the threshold dose at which a pharmacologic response occurs may be lower in small animals. In order to define this relationship, we combined microPET imaging using 11C-raclopride with microdialysis measures of extracellular fluid (ECF) dopamine (DA). In addition, we performed a series of studies in which a known mass of raclopride was microinfused into one striatum prior to a high specific activity (SA) systemic injection of 11C-raclopride. This single-injection approach provided a high and low SA region of radiotracer binding in the same animal during the same scanning session. Our data demonstrate that the binding potential (BP) declines above 3.5 pmol/ml (0.35 microg), with an ED50 of 8.55+/-5.62 pmol/ml. These data also provide evidence that BP may be compromised by masses of raclopride below 2.0 pmol/ml (0.326 microg). Increases in ECF DA were produced by mass doses of raclopride over 3.9 pmol/ml (0.329 microg) with an ED50 of 8.53+/-2.48 pmol/ml. Taken together, it appears that an optimal range of raclopride mass exists between 2.0 and 3.5 pmol/ml, around which the measured BP can be compromised by system sensitivity, endogenous DA, or excessive competition with unlabeled compound.


Subject(s)
Brain/diagnostic imaging , Carbon Isotopes/pharmacokinetics , Dopamine Antagonists/pharmacokinetics , Microdialysis/methods , Positron-Emission Tomography/methods , Raclopride/pharmacokinetics , Animals , Binding, Competitive/drug effects , Brain/anatomy & histology , Brain/metabolism , Brain Mapping , Carbon Isotopes/blood , Dopamine Antagonists/blood , Dose-Response Relationship, Drug , Functional Laterality , Male , Raclopride/blood , Rats , Rats, Sprague-Dawley , Time Factors
19.
J Nucl Med ; 44(5): 815-22, 2003 May.
Article in English | MEDLINE | ID: mdl-12732684

ABSTRACT

UNLABELLED: A new generation of commercial animal PET cameras may accelerate drug development by streamlining preclinical testing in laboratory animals. However, little information on the feasibility of using these machines for quantitative PET in small animals is available. Here we investigate the reproducibility of microPET imaging of (11)C-raclopride in the rat brain and the effects of tracer-specific activity and photon scatter correction on measures of D2 receptor (D2R) availability. METHODS: Sprague-Dawley rats (422 +/- 29 g; n = 7) were anesthetized with ketamine/xylazine and catheterized for tail vein injection of (11)C-raclopride. Each animal was positioned prone in the microPET, centering the head in the field of view. MicroPET data was collected for 60 min-starting at (11)C-raclopride injection-and binned into 24 time frames (6 x 10 s, 3 x 20 s, 8 x 60 s, 4 x 200 s, 3 x 600 s). In 3 studies, (11)C-raclopride was administered a second time in the same animal, with 2-4 h between injections. In a fourth animal, raclopride (1 mg/kg) was coinjected with (11)C-raclopride for the second injection. Three rats received a single dose of (11)C-raclopride. The range of doses for all studies was 6.11-18.54 MBq (165-501 micro Ci). The specific activity at injection was 4.07-48.1 GBq/ micro mol (0.11-1.3 Ci/ micro mol). Region-of-interest analysis was performed and the distribution volume ratio (DVR) was computed for striatum/cerebellum using sinograms uncorrected and corrected for scatter using a tail-fit method. RESULTS: Test-retest results showed that the (11)C-raclopride microPET DVR was reproducible (change in DVR = -8.3% +/- 4.4%). The average DVR from 6 rats injected with high specific activity (<4 nmol/kg) was 2.43 +/- 0.19 (coefficient of variation = 8%). The DVR for the blocking study was 1.23. The DVR depended on the mass of tracer (11)C-raclopride injected for doses >1.5 nmol/kg. Scatter fractions within the rat head were approximately 25%-45% resulting in an average increase of DVR of 3.5% (range, 0%-10%) after correction. CONCLUSION: This study shows that the (11)C-raclopride microPET-derived DVR is reproducible and suitable for studying D2R availability in the rat brain. MicroPET sensitivity was sufficient to determine reproducible DVRs from (11)C-raclopride injections of 9.25 MBq (approximately 250 micro Ci). However, the effect of tracer mass on the DVR should be considered for studies using more than approximately 1-2 nmol/kg raclopride, and scatter correction has a measurable impact on the results.


Subject(s)
Carbon Radioisotopes , Raclopride/metabolism , Receptors, Dopamine D2/analysis , Scattering, Radiation , Tomography, Emission-Computed , Animals , Male , Rats , Rats, Sprague-Dawley , Reproducibility of Results
20.
Neuropsychopharmacology ; 27(2): 163-70, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12093590

ABSTRACT

Although stress is an extensively investigated phenomenon, the effects of specific stressors on the pharmacologic activity of routinely administered drugs are less well characterized. We designed the present study to investigate the effect of handling stress on catecholaminergic responsivity following an acute methylphenidate (MP, Ritalin) challenge in the medial prefrontal cortex (mPFC). Norepinephrine (NE) and dopamine (DA) levels were simultaneously measured in 15-min samples of PFC dialysate using HPLC coupled with electrochemical detection. Sprague-Dawley rats were handled for 15 min, which produced an increase from basal extracellular DA and NE levels. Handling stress attenuates the DA response when administered 2 h prior to IP MP, whereas handling stress enhances the DA response when administered simultaneously with IG MP. These findings suggest that persistent alterations in mesocorticolimbic DA-ergic activity are induced by a short exposure to restraint stress as evidenced by the altered response to MP challenge.


Subject(s)
Adrenergic Uptake Inhibitors/pharmacology , Catecholamines/metabolism , Handling, Psychological , Methylphenidate/pharmacology , Prefrontal Cortex/drug effects , Presynaptic Terminals/drug effects , Stress, Physiological/metabolism , Acute Disease , Animals , Dopamine/metabolism , Drug Administration Schedule , Extracellular Space/drug effects , Extracellular Space/metabolism , Male , Microdialysis , Motor Activity/drug effects , Motor Activity/physiology , Neural Pathways/drug effects , Neural Pathways/metabolism , Neural Pathways/physiopathology , Norepinephrine/metabolism , Prefrontal Cortex/metabolism , Prefrontal Cortex/physiopathology , Presynaptic Terminals/metabolism , Rats , Rats, Sprague-Dawley , Stress, Physiological/physiopathology , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Ventral Tegmental Area/drug effects , Ventral Tegmental Area/metabolism , Ventral Tegmental Area/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...